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Practicing evidence based medicine relies on making
evidence from clinical research available to support medical
practice. In cardiology or oncology, for example, there is
ample evidence from large, randomized clinical trials on
which to base current practice recommendations. In critical
care, however, there has traditionally been a paucity of high
quality evidence to guide and shape practice.
During the past several years such high quality evidence has
begun to emerge. Examples include the randomized trials of
low versus high tidal volume mechanical ventilation in acute
respiratory distress syndrome (ARDS) [1], daily interruption
of sedation in critically ill patients [2], and activated protein C
in severe sepsis [3]. A major challenge facing critical care is
the expeditious translation of such high quality evidence into
care at the bedside. In addressing this, the specialty will no
doubt benefit from experience accrued by colleagues in other
fields. However, there are obstacles specific to critical care
that may require novel solutions.
Levels of barriers
As has been experienced by other specialties, there may be
logistical barriers to implementing evidence based practice at
the level of the clinician, the institution, or regional and/or
national policy making.
Clinicians face numerous potential barriers. First, if no
guidelines exist, then the clinician may not have the time or
the skill required to appraise peer-reviewed literature
critically. If guidelines already exist, then the clinician may
either not have access to them, may lack the confidence to
act on them without formal, specialized training, or may even
apply them incorrectly. Clinicians may even reject the
evidence out of hand, believing it to be inapplicable.
At the level of the institution, incorporating new evidence into
policy documents depends on the degree to which such
policies influence clinical behavior at that institution.
Furthermore, this influence is tempered by how willing the
institution is to displace long established, but often unproven
provincial practices.
Regionally and/or nationally, implementing evidence based
guidelines requires enormous resources. Health care
systems continue to struggle with how best to disseminate
health care policies, let alone specific evidence based
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Abstract
High quality research evidence is now available to guide and shape the practice of critical care. As the
generation of such evidence increases, the challenge facing critical care medicine will be translation of
this evidence into measurable improvement in patient outcome. Significant barriers to this process of
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nature of translational barriers to incorporation of research evidence into clinical practice and the
conventional approach to surmounting these barriers, and provide examples of barriers and potential
solutions to emerging therapies in critical care.
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guidelines. For example, what educational techniques should
be employed? What measures or standards should be used
to determine compliance with the guidelines? What
techniques should be used to improve compliance? Finally,
how can updated guidelines be introduced without
promoting further confusion? Because national and regional
systems are responsible for socially and geographically
diverse health care environments, all of these issues must
also be adaptable to local needs and circumstances.
At each level, there is also the pervasive problem of cost.
Clinician behavior is modified by many factors, but salary and
reimbursement are among the most important. Practice
guidelines that promote uncompensated work are unlikely to
succeed in the long run, but financial incentives to promote
practice guidelines may be expensive, difficult to construct,
and potentially unethical.
For institutions, practice guidelines may be deemed
unaffordable either by hospital administration or by key
members of the health care system. For example, although
the clinicians may wish to use a new and highly effective
therapy, the pharmacy may be reluctant to stock it,
concerned that broad use will be a ‘budget buster’. Such
concern may exist even if the therapy results in net savings
for the hospital as a whole, for example by reducing the
duration of stay in hospital.
At the regional level policy makers may be suspicious that,
although evidence based guidelines may improve health care,
there is an unacceptable increase in costs. Given that health
resources are finite, efficacy is no longer the sole concern
when evaluating an innovation; cost-effectiveness and total
cost burden are crucial when deciding whether to adopt a
potentially common treatment.
An example from cardiology
An example of all these barriers is the use of thrombolytic
therapy for myocardial infarction. Despite widespread
acceptance of its underlying rationale, enormous publicity,
and strong clinical evidence of dramatic reductions in
mortality, it was only slowly accepted into routine clinical
practice. One study conducted 7 years after the introduction
of thrombolytic therapy for myocardial infarction [4] showed
that only half of the patients who might benefit from such
therapy were receiving it. The barriers were multiple. At the
clinician level the decision to institute thromobolytic therapy,
a therapeutic modality that is familiar to most cardiologists,
actually fell to emergency medicine physicians who had
limited first-hand experience with thrombolytic agents and felt
uncomfortable using them.
At the hospital level, there was an inconsistent effort to ensure
emergency medicine physicians were educated in the use of
thrombolytic agents. Compounding this, many institutions
restricted prescribing rights to trained cardiologists, who were
sometimes reluctant to cede this privilege to non-cardiologists
and yet not necessarily prepared to provide 24 hour response
to the emergency department.
At the regional level there was minimal effort to measure
dissemination and to determine whether thrombolytic agents
were being used properly outside of the large academic
centers; only later did circumstantial evidence arise that
smaller hospitals were probably not using thrombolytic
agents as frequently as were larger hospitals [5,6].
Finally, there was concern at all levels regarding the potential
costs of the newer, more expensive thrombolytic agents,
further paralyzing their dissemination despite compelling
cost-effectiveness assessments [7].
Research into implementation
Paralleling the evolution of evidence based medicine has
been research into how evidence can be implemented into
practice – so called ‘implementation research’ [8].
Understanding how individuals and organizations absorb
evidence and implement change has, in select
circumstances, translated into fundamental improvements in
health care. In most cases, however, this understanding
remains elusive and no reliable, widely applicable way to
modify behavior has been discovered. We have learned
much about barriers to research transfer through our failed
attempts to modify behavior.
Success in modifying a discrete aspect of medical practice
has invariably been achieved through integrated,
multidisciplinary strategies that meld concepts and
techniques from epidemiology, education, marketing,
psychology, sociology, and economics. Ways in which the
principles of implementation research might currently be
applied to high quality evidence include the following.
Formulating evidence based guidelines that promote
best practice initiatives at international and national
levels
Although an important first step is to gain national and
international consensus, this alone is insufficient because
hundreds of guidelines exist but are routinely ignored.
Developing and funding specific regional policies
This is theoretically important but difficult to accomplish
practically. Although there have been important successes,
such as a national cervical cancer screening program in the
UK and elsewhere, such programs benefited from having
financial incentives for physicians, relatively straightforward
auditing procedures, and considerable political and societal
pressure. Despite their success, however, even cervical
cancer screening has not been adopted in all developed
countries. Regional programs for more obscure and complex
practices will only be more difficult, have greater costs, and
involve more challenging political and social issues.Aggressive outreach programs to local opinion leaders
Recruiting influential members of local medical
establishments to champion the cause of evidence based
medicine is an essential element of the process. Integral to
this role is the local ‘tailoring’ of best evidence to foster a
sense of local ‘ownership’.
Incorporating tools to facilitate clinical decision making
Such tools can vary in complexity from updated textbooks to
complex, computer-based algorithms that provide decisions
based on actual patient data. Although there has been early
success using computer-driven decision support tools in the
intensive care unit (ICU) [9], their use has generally been
limited to clinical trials and specific institutions. Wider use
remains difficult because of cost and development issues.
Regional and institutional measuring of compliance,
processes of care, and patient outcomes
Systematic measurement is key to quality improvement: it
facilitates the identification and correction of barriers to
implementation. Examples include the large, statewide
cardiac surgery outcomes registries that provide feedback on
which centers generate best outcomes [6,10]. Regional
initiatives to measure ICU care now exist in many countries in
Europe, in Australia, and in New Zealand, but have been
limited in the USA [11]. However, most current efforts have
lacked sufficient detail on how care was provided. This limits
our understanding of why outcomes differ, hampering their
value for process improvement and compliance with best
practice standards.
Economic analysis demonstrating the cost-
effectiveness of new treatments that may place
sizable demands on health resources
Well-conducted economic analyses inform policy makers by
quantifying the tradeoffs of costs and benefits probably
better than any other tool.
Anticipating best practice dissemination in
critical care
Given the barriers to implementing best evidence, and the
limitations of existing strategies to overcome them, what
might some of the issues be for the dissemination of best
practice in critical care?
Activated protein C
This drug enters clinical practice with much the same fanfare
as did thrombolysis. There are a number of parallels. First, at
the clinician level, how the drug works and the concept of the
intersection between the coagulation and inflammatory
responses in sepsis are not yet widely assimilated. Second,
there is a temporal component to administering activated
protein C, so once again emergency medicine physicians
may be called upon to be the vanguard for instituting a new
therapy, even though it was developed in a different field of
medicine. Third, the complexity of screening patients for this
therapy will undoubtedly slow its entry into widespread use.
Even among those who specialize in treating the critically ill,
reluctance to incorporate activated protein C into routine
clinical practice may result, for example, from skepticism of
its mortality benefit in the face of the present lack of
outcomes data beyond the conventional 28-day study period.
At the institutional and regional levels, cost becomes a major
issue. The lack of long-term outcomes data will hamper its
adoption by institutional and regional policy makers who must
focus on cost versus benefit. The enormity of the financial
commitment required to implement routine use of this therapy
at the regional level might prompt a careful auditing system
that includes proactive screening of all patients with severe
sepsis. However, the introduction of such a system is
daunting from a financial and logistical standpoint.
Low tidal volume ventilation
The case of low tidal volume, plateau-pressure-limited
mechanical ventilation for lung injury and ARDS reflects a
different set of problems. Although no new pharmacologic or
technologic innovation is needed to provide this therapy, its
promotion will not be without a significant educational cost.
Initially, efforts may be restricted to critical care practitioners
and allied health professionals, but if the scope of this
technique were to be broadened to other patient subsets
then the educational effort may need to take on monumental
proportions.
Even within the ICU, other attending physicians, such as
trauma surgeons or pulmonologists, may have a different
attitude or opinion regarding low tidal volumes to that of the
intensivist. Significant biases may have to be overcome to
convince providers of the ‘unnatural’ pattern of ventilation
that is required to achieve the goals of a low tidal volume,
plateau-limited approach. Regions and institutions may
actually have a negative incentive with regard to this
technique if they are concerned, perhaps unjustly, that the
cost of longer ICU stay accrues with improved survival. This
may be particularly true in view of the poor long-term
outcome of ARDS survivors. This negative incentive may
undermine screening and auditing efforts that will be
essential to ensure that all patients who may benefit from the
technique actually receive it.
Daily interruption of sedation
Daily interruption of sedative/hypnotic therapy in critically ill
patients to avoid excessive sedation will probably face similar
dissemination problems to those of low-tidal volume
strategies. First, clinicians may be very reluctant to awaken
patients they believe ‘require’ sedation. Overcoming this
traditional care bias will be difficult and require considerable
education for all members of the ICU team. Again, the
intensivist, the ICU nurse, and other physicians involved in
the patient’s care may have opinions about the ‘right’ way to
sedate a patient, and educational strategies to convince one
Available online http://ccforum.com/content/6/1/011member of the team may not be successful in convincing
others.
Successful introduction of daily interruption of sedation
probably requires a comprehensive monitoring and
compliance program. This obviously costs money – money
that the hospital may be unwilling to spend, especially if it
fails to understand the importance of this care approach.
Similarly, this level of detail regarding ICU care is simply not
on the ‘radar’ screen at the regional or national policy level,
and it is therefore unlikely that any system-wide initiatives will
be introduced to ensure compliance, despite the large
improvement in patient outcomes recently reported by Kress
and colleagues [2]. Overcoming these problems requires
considerable raising of awareness by local thought leaders,
perhaps with further studies demonstrating the optimal way
to disseminate best practice protocols. Again, however, this
costs money, and the funding will probably have to come
from federal agencies because there is no obvious industry
stakeholder.
Conclusion
Translating high quality evidence into improved patient
outcomes is a complex process. The changes required are
substantial and will not be without significant cost, although
lessons can be learned from the introduction of new
therapies in other fields. Comprehensive education programs
aimed at physicians of all specialties, not just critical care
specialists, will be the most effective. Taking the lead in these
educational efforts should be multidisciplinary groups of
physician ‘thought leaders’, whose role will be to ensure that
high quality evidence makes its way from the international
and national levels to the regional and local levels.
Comprehensive economic analysis, incorporating emerging
outcomes data, may help institutional and regional planners
to justify the widespread use of new therapies; practical
screening, auditing, and compliance systems are almost
certainly necessary. Development of such tools and ongoing
research to discover optimal ways to overcome barriers to
transfer of research will be expensive, and funding cannot
only come from industry but also from federal agencies.
However, if we learn how to translate high quality evidence
into care at the bedside now, we will not only improve quality
of health care but also ensure more rapid dissemination of
future advances.
Competing interests
DCA provides consulting to Eli Lilly & Company (Indianapolis,
IN) and has received research funds from Eli Lilly & Company
related to the evaluation of activated Protein C. DCA also has
NIH funding to evaluate clinical and economic outcomes of
patients on the NIH ARDS Network.
References
1. The ARDS Network authors for the ARDS Network: Ventilation
with lower tidal volumes as compared with traditional tidal
volumes for acute lung injury and the acute respiratory dis-
tress syndrome. N Engl J Med 2000, 342:1301-1308.
2. Kress JP, Pohlman AS, O’Connor MF, Hall JB: Daily interruption
of sedative infusions in critically ill patients undergoing
mechanical ventilation. N Engl J Med 2000, 342:1471-1477.
3. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF,
Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely
EW, Fisher CJ Jr, for the PROWESS Study Group: Efficacy and
safety of recombinant human activated protein C for severe
sepsis. N Engl J Med 2001, 344:699-709.
4. Ketley D, Woods KL: Impact of clinical trials on clinical prac-
tice: Example of thrombolysis for acute myocardial infarction.
Lancet 1993, 342:891-894.
5. McClellan M, McNeil BJ, Newhouse JP: Does more intensive
treatment of acute myocardial infarction in the elderly reduce
mortality? Analysis using instrumental variables. JAMA 1994,
272:859-866.
6. PA Health Care Cost Containment Council: Focus on Heart
Attack in Western Pennsylvania: A 1993 Summary Report for
Health Benefits Purchasers, Health Care Providers, Policymak-
ers, and Consumers. Harrisburg, PA: PHCCC; 1996.
7. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong
PW, Barbash G, White H, Simoons ML, Nelson CL: Cost effec-
tiveness of thrombolytic therapy with tissue plasminogen
activator as compared with streptokinase for acute myocar-
dial infarction. N Engl J Med 1995, 332:1418-1424.
8. Grol R, Jones R: Twenty years of implementation research.
Fam Pract 2000, 17(suppl 1):S32-S35.
9. Morris AH: Protocol management of adult respiratory distress
syndrome. New Horiz 1993, 1:593-602.
10. Hannan EL, Siu AL, Kumar D, Kilburn H Jr, Chassin MR: The
decline in coronary artery bypass graft surgery mortality in
New York State. The role of surgeon volume. JAMA 1995,
273:209-213.
11. Sirio CA, Shepardson LB, Rotondi AJ, Cooper GS, Angus DC,
Harper DL, Rosenthal GE: Community-wide assessment of
intensive care outcomes using a physiologically-based prog-
nostic measure: Implications for critical care delivery from
Cleveland Health Quality Choice. Chest 1999, 115:793-801.
Critical Care    February 2002 Vol 6 No 1 Kalassian et al.